Electromed, Inc. reported the three months ended March 31, 2026 results: revenue $ 18.6 million, net income $ 3.0 million, or $ 0.35 per diluted share, EPS $ 0.35 per diluted share.
“today announced financial results for the three and nine months ended March 31, 2026 (“ Q3 FY 2026 ”). Q3 FY 2026 Company Highlights ● Net revenues increased 18.4% to a record $ 18.6 million in Q3 FY 2026, from $ 15.7 million in the third quarter of the prior fiscal year, led by an 18.6% increase in the core homecare market. ● Operating income increased to a record $”
Material Agreements
Electromed, Inc. entered into Credit Agreement with BMO Bank N.A. valued at $10,000,000 revolving line of credit (effective 2025-12-16).
“On December 16, 2025, Electromed, Inc. (the “Company”) entered a Credit Agreement (the “Credit Agreement”) with BMO Bank N.A. (“Lender”), as lender.”
Debt Financings
Electromed, Inc. incurred credit facility of $10,000,000 revolving line of credit with BMO Bank N.A. at one-month Term SOFR plus 1.75% maturing December 16, 2026.
“The Credit Agreement provides the Company with a senior security credit facility with a $10,000,000 revolving line of credit (the “Credit Facility”). The Credit Agreement provides that the Credit Facility will mature on December 16, 2026. Any borrowings under the Credit Facility will bear interest at one-month Term SOFR plus 1.75%, payable monthly.”
Earnings Releases
Electromed, Inc. reported the three months ended March 31, 2024 results: revenue $13.9 million, net income $1,493,000, EPS $0.17 per diluted share.
“Net revenues increased 15% to a record $13.9 million in Q3 FY 2024, from $12.1 million in the third quarter of the prior fiscal year. ● Gross margins were 75% of net revenues in the third quarters of both the current and prior fiscal years. ● Operating income increased by 54% to $1,841,000 or 13% of revenue, compared with $1,196,000 or 10% of revenue in the third quarter of the prior fiscal year. ● Net income was $1,493,000 for the quarter, or $0.17 per diluted share, compared to $1,075,000, or $0.12 per diluted share in the third quarter of the prior fiscal year.”
Earnings Releases
Electromed, Inc. reported Q2 FY 2024 results: revenue $13.7 million, net income $1,674,000, EPS $0.19 per diluted share.
“Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended December 31, 2023 (“Q2 FY 2024”). Q2 FY 2024 Financial Highlights ● Net revenue increased 17% to a record $13.7 million in Q2 FY 2024, from $11.7 million in the second quarter of the prior fiscal year. ● Gross margins were 77% of revenue, compared to 74% in the second quarter of the prior fiscal year. ● Operating income was a record $2,263,000 or 16.5% of revenue, compared with $1,274,000 or 10.9% of revenue in the second quarter of the prior fiscal year. ● Net income was a record $1,674,000 for the quarter, or $0.19 per diluted share, compared to $977,000, or $0.11 per diluted share in the second quarter of the prior fiscal year.”
Debt Financings
Electromed, Inc. amended revolving credit of $2,500,000 with Choice Financial Group at prime rate less 1.00% maturing December 18, 2025.
“On December 13, 2023, Electromed, Inc. (the "Company") renewed its $2,500,000 revolving line of credit with Choice Financial Group pursuant to a supplemental rider to the existing Business Loan Agreement (Asset Based) dated December 18, 2019. The rider provides that the line of credit will be extended for an additional two years and is now scheduled to mature on December 18, 2025. Interest on borrowings on the line of credit, if any, will remain at prime rate less 1.00%, with no interest rate floor and payable monthly.”
Material Agreements
Electromed, Inc. amended Business Loan Agreement (Asset Based) with Choice Financial Group valued at $2,500,000 (effective 2023-12-13).
“On December 13, 2023, Electromed, Inc. (the "Company") renewed its $2,500,000 revolving line of credit with Choice Financial Group pursuant to a supplemental rider to the existing Business Loan Agreement (Asset Based) dated December 18, 2019.”
Shareholder Votes
Electromed, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2023-11-10 meeting.
“4. Our shareholders approved, on a non-binding and advisory basis, our executive compensation, with voting as follows: For Against Abstain Broker Non-Votes 3,990,197 54,887 22,218 1,282,424”
Shareholder Votes
Electromed, Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending June 30, 2024 at the 2023-11-10 meeting.
“3. Our shareholders ratified the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024, with voting as follows: For Against Abstain 5,256,837 44,804 48,085”
Shareholder Votes
Electromed, Inc. shareholders approved Approval of the Electromed, Inc. 2023 Equity Incentive Plan at the 2023-11-10 meeting.
“2. Our shareholders approved the Electromed, Inc. 2023 Equity Incentive Plan with voting as follows: For Against Abstain Broker Non-Votes 3,900,794 146,689 19,819 1,282,424”
Shareholder Votes
Electromed, Inc. shareholders approved Election of directors for a one-year term at the 2023-11-10 meeting.
“At the annual meeting of shareholders of Electromed, Inc. (the “Company”) held on November 10, 2023, the following proposals, each as described in further detail in the definitive proxy statement filed on September 26, 2023 , were voted upon by our shareholders as set forth below: 1. The following individuals designated by our Board of Directors (the “Board”) as nominees for director were elected for a one-year term or until a successor has been elected and qualified, thereby setting the number of directors at eight, with voting as follows: Name For Withheld Broker Non-Votes James L. Cunniff 4,043,526 23,776 1,282,424 Stan K. Erickson 3,934,581 132,721 1,282,424 Gregory J. Fluet 3,886,683 180,619 1,282,424 Joseph L. Galatowitsch 4,036,919 30,383 1,282,424 Kathleen S. Skarvan 4,026,909 40,393 1,282,424 Andrew J. Summers 3,308,087 759,215 1,282,424 Kathleen A. Tune 3,416,625 650,677 1,282,424 Andrea M. Walsh 3,928,188 139,114 1,282,424”
Earnings Releases
Electromed, Inc. reported the three months ended September 30, 2023 results: revenue $12.3 million, net income $155,000, EPS $0.02 per diluted share.
“Net revenue increased 16% to $12.3 million in Q1 FY 2024”
Earnings Releases
Electromed, Inc. reported the three months and full year ended June 30, 2023 results: revenue $13.6 million, net income $1.0 million, EPS $0.12 per diluted share.
“financial results for the three months (“Q4 FY 2023”) and full year (“FY 2023”) ended June 30, 2023. Q4 FY 2023 Financial Highlights ● Net revenue increased 21% to a record $13.6 million in Q4 FY 2023, from $11.3 million in Q4 of the prior year. ● Operating income totaled $1.5 million in Q4 FY 2023, compared to $0.5 million in Q4 FY 2022. ● Net income was $1.0”
Christopher G. Holland departed as Chief Commercial Officer at Electromed, Inc..
“On June 13, 2023, Electromed, Inc. (the “Company”) reached a mutual agreement with its Chief Commercial Officer, Christopher G. Holland, to end his employment effective as of June 23, 2023.”
Lee A. Jones departed as Director at Electromed, Inc..
“current director Lee A. Jones will not stand for election and is expected to serve the rema”
James L. Cunniff was appointed as Director at Electromed, Inc..
“The Company's board of directors (the "Board") has also approved an increase in its size to nine members and appointed Mr. Cunniff to serve as an additional director effective as of the same date.”
James L. Cunniff was appointed as Chief Executive Officer and President at Electromed, Inc..
“On June 5, 2023, Electromed, Inc. (the "Company") announced the appointment of James L. Cunniff to serve as its next Chief Executive Officer and President, beginning July 1, 2023.”
Earnings Releases
Electromed, Inc. reported the three months ended December 31, 2022 results: revenue $11.7 million, net income $977,000, EPS $0.11 per diluted share.
“innovative airway clearance technologies, today announced financial results for the three months ended December 31, 2022 (“Q2 FY 2023”). Q2 FY 2023 Highlights ● Net revenue was $11.7 million for the three months ended December 31, 2022, a quarterly record and a 15% increase from $10.2 million for the three months ended December 31, 2021 (“Q2 FY 2022”) ●”
Kathleen S. Skarvan was appointed as Chair of the Board at Electromed, Inc..
“Following the Retirement Date, Ms. Skarvan is expected to serve as a non-employee member and Chair of the Board”
Kathleen S. Skarvan departed as President and Chief Executive Officer at Electromed, Inc..
“Kathleen S. Skarvan, the President and Chief Executive Officer of the Company, notified the Company of her intention to retire from the Company effective on or about July 1, 2023”
Shareholder Votes
Electromed, Inc. shareholders approved Advisory vote on executive compensation at the 2022-11-11 meeting.
“3. Our shareholders approved, on a non-binding and advisory basis, our executive compensation, with voting as follows: For Against Abstain Broker Non-Votes 4,312,956 170,780 545,430 1,045,889”
Shareholder Votes
Electromed, Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm at the 2022-11-11 meeting.
“2. Our shareholders ratified the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023, with voting as follows: For Against Abstain 5,522,296 6,431 546,328”
Shareholder Votes
Electromed, Inc. shareholders approved Election of eight director nominees at the 2022-11-11 meeting.
“1. The following individuals designated by our Board of Directors (the “Board”) as nominees for director were elected for a one-year term or until a successor has been elected and qualified, thereby setting the number of directors at eight, with voting as follows: Name For Withheld Broker Non-Votes Stan K. Erickson 4,277,371 751,795 1,045,889 Gregory J. Fluet 4,217,354 811,812 1,045,889 Joseph L. Galatowitsch 4,369,790 659,376 1,045,889 Lee A. Jones 3,032,167 1,996,999 1,045,889 Kathleen S. Skarvan 4,385,793 643,373 1,045,889 Andrew J. Summers 3,704,285 1,324,881 1,045,889 Kathleen A. Tune 4,375,318 653,848 1,045,889 Andrea M. Walsh 4,231,084 798,082 1,045,889”
Earnings Releases
Electromed, Inc. reported the three months ended September 30, 2022 results: revenue $10.7 million, net income $81,000, EPS $0.01 per diluted share.
“Net revenue was $10.7 million for the three months ended September 30, 2022, a 7% increase from $10.0 million for the three months ended September 30, 2021 ("Q1 FY 2022")”
Michelle C. Wirtz changed role as interim Chief Financial Officer, Treasurer and Secretary at Electromed, Inc..
“Michelle C. Wirtz, the Company's interim Chief Financial Officer, Treasurer and Secretary, will cease to serve in those positions upon the commencement of Mr. Nagel's employment.”
Bradley M. Nagel was appointed as Chief Financial Officer, Treasurer and Secretary at Electromed, Inc..
“On October 24, 2022, Electromed, Inc. (the "Company") announced the selection of Bradley M. Nagel to serve as the Company's next Chief Financial Officer, Treasurer and Secretary, beginning November 14, 2022.”
Andrew J. Summers was elected as Director at Electromed, Inc..
“The information regarding the election of Andrew J. Summers to serve as a member of the Board set forth in Item 1.01 above is incorporated herein by reference.”
Michael J. MacCourt departed as Chief Financial Officer, Treasurer and Secretary at Electromed, Inc..
“Michael J. MacCourt, the Company’s former Chief Financial Officer, Treasurer and Secretary, ceased to serve in those positions upon the commencement of Ms. Wirtz’s promotion.”
Michelle C. Wirtz was appointed as Interim Chief Financial Officer, Treasurer and Secretary at Electromed, Inc..
“Michelle C. Wirtz commenced service as Interim Chief Financial Officer, Treasurer and Secretary of Electromed, Inc. (the “Company”), effective June 1, 2022.”
Michelle C. Wirtz was appointed as Interim Chief Financial Officer, Treasurer and Secretary at Electromed, Inc..
“we announced the selection of Michelle C. Wirtz to serve as the Company’s Interim Chief Financial Officer, Treasurer and Secretary, beginning June 1, 2022.”
Michael J. MacCourt resigned as Chief Financial Officer at Electromed, Inc..
“Michael J. MacCourt, our current Chief Financial Officer, notified us that he intends to resign his employment with Electromed, Inc. (the “Company”) on or about July 1, 2022 to pursue a new opportunity outside of corporate finance.”
George Winn departed as Director at Electromed, Inc..
“each of Mr. Craney and Dr. Winn has indicated his intention to retire from the Board effective as of the 2022 Annual Meeting and, as a result, will not to stand for reelection.”
Steve Craney departed as Director at Electromed, Inc..
“each of Mr. Craney and Dr. Winn has indicated his intention to retire from the Board effective as of the 2022 Annual Meeting and, as a result, will not to stand for reelection.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.